Galmed Pharmaceutica (GLMD) Stock Price, Quote & News

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 693 8448

Fax: 972 3 693 8447

Website: galmedpharma.com

Address:

16 Abba Hillel Road, Ramat Gan, Israel

CalculatedSwing Oct. 27 at 9:33 PM

$NNVC coming again soon. $GLMD $BIVI $GFAI $CORZ

0 · Reply

getsometoday Oct. 27 at 7:59 PM

$GLMD where’s lookgood? Did we lose him

1 · Reply

getsometoday Oct. 27 at 7:07 PM

$GLMD 😏

0 · Reply

madan_shatri Oct. 27 at 6:51 PM

$GLMD I told this very very clearly a month ago that no big ticket news will be coming up before 28th Oct SHs meeting. I was right ! I also said that no big ticket news will be expected at least 2 weeks after the 28th Oct SH meeting. Lets if that will also be comes out right or wrong. I also said that for these couple of months, SP will reamin under pressure of slide down. So we didn't gain a penny ever since. I also predicted that SP will dive down big if no news comes out by end of Nov. Tax loss selling will have maximum impact of these undirectional penny stocks. But I praying and hoping that there must be something great coming up sometimes in Mid or end of Nov. I am very cautiously bullish

1 · Reply

Mattherhorn Oct. 27 at 6:46 PM

$GLMD looks like the only major discussion point for tomorrow is the increase of OS. Is there any other catalyst for this? I thought there would be news by now, but looks like I am wrong.

0 · Reply

Shakattack31 Oct. 27 at 4:41 PM

$GLMD why oh why

0 · Reply

Mjv22101 Oct. 27 at 2:20 PM

$GLMD

0 · Reply

whippster Oct. 27 at 12:28 PM

$GLMD

1 · Reply

whippster Oct. 27 at 12:13 PM

$GLMD are we still going to hear something on the 28th? Which is tomorrow

0 · Reply

Morpomex Oct. 27 at 11:02 AM

$GLMD

0 · Reply

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 25, 2025, 7:30 AM EDT - 2 months ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

May 27, 2025, 8:00 AM EDT - 5 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 22, 2025, 8:00 AM EDT - 5 months ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 6 months ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Apr 28, 2025, 8:00 AM EDT - 6 months ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 17, 2025, 8:30 AM EDT - 6 months ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 15, 2025, 8:30 AM EDT - 6 months ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 7 months ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 2, 2025, 4:10 PM EDT - 7 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 20, 2025, 8:55 AM EDT - 7 months ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Apr 4, 2024, 5:06 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Mar 15, 2024, 9:00 AM EDT - 1 year ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 22, 2023, 4:05 PM EDT - 2 years ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 14, 2023, 9:30 AM EDT - 2 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

May 9, 2023, 7:00 AM EDT - 2 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Mar 29, 2023, 5:00 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Feb 8, 2023, 8:00 AM EST - 2 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Jul 7, 2022, 8:27 AM EDT - 3 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

May 17, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 7:30 AM EDT - 3 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 2, 2022, 1:56 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

May 2, 2022, 7:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Apr 28, 2022, 7:00 AM EDT - 3 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 10, 2022, 9:14 AM EST - 4 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Nov 8, 2021, 3:24 PM EST - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 7:30 AM EST - 4 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:00 AM EST - 4 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 1, 2021, 10:10 AM EDT - 4 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Oct 11, 2021, 8:00 AM EDT - 4 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

Aug 16, 2021, 8:00 AM EDT - 4 years ago

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Aug 9, 2021, 11:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript

Aug 5, 2021, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Aug 2, 2021, 9:26 AM EDT - 4 years ago

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial

Aug 2, 2021, 7:30 AM EDT - 4 years ago

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

Jul 29, 2021, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5

May 13, 2021, 6:58 PM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript

CalculatedSwing Oct. 27 at 9:33 PM

$NNVC coming again soon. $GLMD $BIVI $GFAI $CORZ

0 · Reply

getsometoday Oct. 27 at 7:59 PM

$GLMD where’s lookgood? Did we lose him

1 · Reply

getsometoday Oct. 27 at 7:07 PM

$GLMD 😏

0 · Reply

madan_shatri Oct. 27 at 6:51 PM

1 · Reply

Mattherhorn Oct. 27 at 6:46 PM

$GLMD looks like the only major discussion point for tomorrow is the increase of OS. Is there any other catalyst for this? I thought there would be news by now, but looks like I am wrong.

0 · Reply

Shakattack31 Oct. 27 at 4:41 PM

$GLMD why oh why

0 · Reply

Mjv22101 Oct. 27 at 2:20 PM

$GLMD

0 · Reply

whippster Oct. 27 at 12:28 PM

$GLMD

1 · Reply

whippster Oct. 27 at 12:13 PM

$GLMD are we still going to hear something on the 28th? Which is tomorrow

0 · Reply

Morpomex Oct. 27 at 11:02 AM

$GLMD

0 · Reply

VolcanicTrades Oct. 26 at 6:28 PM

$GLMD I don’t see how we wouldn’t at least have the crypto digital assets PR, (like what we bought, and future plans in that space) prior to the ER in November.

0 · Reply

VolcanicTrades Oct. 26 at 5:47 PM

$GLMD

0 · Reply

BankOnTheFuture Oct. 26 at 3:24 PM

$GLMD The # of watchers has gone up by about a 1,000 since September. Verrry interesting.

0 · Reply

Lowlyme Oct. 25 at 2:09 AM

$GLMD LM since 2020. GLTA. Best.

0 · Reply

Lowlyme Oct. 25 at 2:07 AM

$GLMD We are no longer a NASH pharma company. IMO

0 · Reply

VolcanicTrades Oct. 24 at 5:56 PM

$GLMD sideways trading generally not bearish. Basing for the move!!!! Come on Allen! Crypto treasury / aramchol

1 · Reply

Morpomex Oct. 24 at 4:43 PM

$GLMD Let’s see what’s on the 28th next week, and Q3 news in beginning of November bring.

1 · Reply

VolcanicTrades Oct. 24 at 3:37 PM

$GLMD

0 · Reply

Morpomex Oct. 23 at 3:52 PM

$GLMD Soon.

0 · Reply

Profitfire Oct. 23 at 2:06 PM

$GLMD this here will jump soon like $TNON

1 · Reply

Trumpy14 Oct. 22 at 8:54 PM

$GLMD im still bullish here but this has turned into a painful hold. So many other good plays in the market right now. Cant wait to get rid of this one. Hopefully we get some news very soon.

2 · Reply

madan_shatri Oct. 22 at 4:57 PM

$GLMD Window is shrinking fast. Need good news soon. Tax loss season will be starting soon

1 · Reply

Market Cap	2.28M
Revenue (ttm)	0.00
Net Income (ttm)	-7.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	97,300
Avg Vol	131,368
Day's Range	N/A - N/A
Shares Out	1.65M
Stochastic %K	30%
Beta	0.50
Analysts	Hold
Price Target	$12.00